GoodRx (NASDAQ:GDRX) Trading 8.7% Higher - Should You Buy?

Key Points

• GoodRx shares jumped about 8.7% intraday to $2.565 on Friday while trading volume was roughly 26% below its recent average.
• Analyst sentiment is mixed with an average rating of "Hold" and a consensus target of $3.85; notable moves include Goldman Sachs cutting its price target to $2.50.
• The company reported quarterly EPS of $0.09 (in line with estimates) and revenue of $194.79 million, a slight 1.9% decline year-over-year, and has a market cap near $874 million.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s share price traded up 8.7% on Friday . The company traded as high as $2.54 and last traded at $2.5650. 1,919,610 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 2,605,224 shares. The stock had previously closed at $2.36.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. The Goldman Sachs Group lowered their price objective on GoodRx from $4.00 to $2.50 and set a "neutral" rating for the company in a research report on Monday, March 2nd. JPMorgan Chase & Co. reissued a "neutral" rating on shares of GoodRx in a research report on Friday, February 27th. Bank of America reissued a "reduce" rating on shares of GoodRx in a research report on Monday, January 5th. Wall Street Zen cut GoodRx from a "buy" rating to a "hold" rating in a research report on Sunday, January 25th. Finally, Leerink Partners reissued an "outperform" rating and issued a $3.00 price objective on shares of GoodRx in a research report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $3.85.

GoodRx Trading Up 8.1%

The stock has a 50-day simple moving average of $2.19 and a 200 day simple moving average of $2.63. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. The company has a market cap of $873.55 million, a price-to-earnings ratio of 28.34, a PEG ratio of 1.58 and a beta of 1.47.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting analysts' consensus estimates of $0.09. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The company had revenue of $194.79 million during the quarter, compared to analysts' expectations of $193.27 million. During the same quarter in the previous year, the firm posted $0.09 EPS. The firm's revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts predict that GoodRx Holdings, Inc. will post 0.15 EPS for the current fiscal year.

Institutional Trading of GoodRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. AQR Capital Management LLC lifted its position in GoodRx by 124.4% during the 1st quarter. AQR Capital Management LLC now owns 282,320 shares of the company's stock worth $1,245,000 after acquiring an additional 156,482 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of GoodRx by 7.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company's stock valued at $3,455,000 after buying an additional 54,783 shares during the period. Jane Street Group LLC acquired a new position in shares of GoodRx in the 1st quarter valued at about $370,000. Creative Planning acquired a new position in shares of GoodRx in the 2nd quarter valued at about $93,000. Finally, Cetera Investment Advisers acquired a new position in shares of GoodRx in the 2nd quarter valued at about $50,000. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.